Completion of the first implantation procedure marks the start of Abbott’s pivotal deep brain stimulation trial in ...

Case marks the beginning of a multi-site pivotal trial to evaluate Abbott’s system for management of treatment-resistant ...

Though DBS will not cure the progression of the disease, it will improve the quality of life of advanced PD patients.

A team of experts from the Icahn School of Medicine at Mount Sinai has become the first in the United States to perform a ...

The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...

Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced the launch of the aPAP ClearPath Dried Blood Spot (DBS) Test in the U.S., an ...

For the one million people diagnosed with Parkinson's disease in the United States, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global ...

The FDA approves BrainSense Adaptive deep brain stimulation and electrode identifier technology for the treatment of ...

DBS is similar to a cardiac pacemaker ... Motor Control and Neuromodulation Lab at Stanford University School of Medicine. "The transformative personalized care we can achieve through automatic ...